The potential of human nasal colonization with Streptococcus pneumoniae as a universal pneumococcal vaccine

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 8, 2013, Pages 794-795

  Gonzalez, Blanca E ^a,b   Jacobs, Michael R ^c,d  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; MATERNAL ANTIBODY; OUTER MEMBRANE PROTEIN A; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE;

BACTERIAL COLONIZATION; CD4+ T LYMPHOCYTE; COMPLEMENT DEPOSITION; CROSS PROTECTION; EDITORIAL; HUMAN; INFECTION; MUCOSAL IMMUNITY; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALS; CARRIER STATE; FEMALE; HUMANS; MALE; NASAL MUCOSA; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84876848071     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201302-0361ED     Document Type: Editorial

References (20)

1. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41.
2. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1668-1674.
3. Kaplan SL, Barson WJ, Lin PL, Stovall SH, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO Jr. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010;125:429-436.
4. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-819.
5. Musher DM. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis 2012;55:265-267.
6. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011;52:633-640.
7. Ridda I, Musher DM. Is there a potential role for protein-conjugate pneumococcal vaccine in older adults? Australas Med J 2012;5:231-235.
8. McCool TL, Cate TR, Moy G, Weiser JN. The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 2002;195:359-365. (Pubitemid 34461494)
9. Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AKA, Pennington SH, Bricio Moreno L, Moreno AT, Miyaji EN, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013;187:855-864.
10. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004;4: 144-154. (Pubitemid 38293138)
11. Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, Huebner RC, Virolainen A, Swiatlo E, Hollingshead SK. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000;68:796-800. (Pubitemid 30056538)
12. Lebon A, Verkaik NJ, Labout JA, de Vogel CP, Hooijkaas H, Verbrugh HA, van Wamel WJ, Jaddoe VW, Hofman A, Hermans PW, et al. Natural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study. Infect Immun 2011;79:1680-1687.
13. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4.
14. Hulten KG, Kaplan SL, Lamberth LB, Barson WJ, Romero JR, Lin PL, Bradley JS, Givner LB, Tan TQ, Hoffman JA, Mason EO. Changes in pediatric Streptococcus pneumoniae serotype 19A invasive infections in children from 1993 to 2011. J Clin Microbiol 2013:1294-1297.
15. Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, et al. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS ONE 2010;5:e10863.
16. Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, Ferreira JM Jr, Pimenta FC, Andrade AL, Miyaji EN. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 2010; 17:439-446.
17. Malley R, Anderson PW. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci USA 2012;109:3623-3627.
18. Wright AK, Ferreira DM, Gritzfeld JF, Wright AD, Armitage K, Jambo KC, Bate E, El Batrawy S, Collins A, Gordon SB. Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage. PLoS Pathog 2012;8:e1002622.
19. Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, Flechtner JB, Higgins DE, Malley R. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011;9: 158-165.
20. Regev-Yochay G, Dagan R, Raz M, Carmeli Y, Shainberg B, Derazne E, Rahav G, Rubinstein E. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. JAMA 2004;292:716-720. (Pubitemid 39062526)